866-997-4948(US-Canada Toll Free)

Rhabdomyosarcoma - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 177 Pages

Rhabdomyosarcoma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H1 2017, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.

Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 6, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 2, 1 and 1 molecules, respectively.

Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rhabdomyosarcoma - Overview 6
Rhabdomyosarcoma - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Rhabdomyosarcoma - Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 17
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Rhabdomyosarcoma - Companies Involved in Therapeutics Development 24
Bellicum Pharmaceuticals Inc 24
Boehringer Ingelheim GmbH 24
Bristol-Myers Squibb Company 25
Celgene Corp 25
CytRx Corp 26
EpiZyme Inc 26
Exelixis Inc 27
Iproteos SL 27
Ipsen SA 28
MacroGenics Inc 28
Novartis AG 29
Noxxon Pharma AG 29
Pfizer Inc 30
Shionogi & Co Ltd 30
Taiho Pharmaceutical Co Ltd 31
Rhabdomyosarcoma - Drug Profiles 32
afatinib dimaleate - Drug Profile 32
aldoxorubicin hydrochloride - Drug Profile 46
AT-69 - Drug Profile 61
axitinib - Drug Profile 62
cabozantinib s-malate - Drug Profile 68
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 87
Cellular Immunotherapy for Oncology - Drug Profile 89
Cellular Immunotherapy to Target GD2 and CD56 for Solid Tumors - Drug Profile 91
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 92
Celyvir - Drug Profile 93
crizotinib - Drug Profile 94
enoblituzumab - Drug Profile 101
everolimus - Drug Profile 104
ipilimumab + nivolumab - Drug Profile 118
irinotecan hydrochloride - Drug Profile 123
MAL-3101 - Drug Profile 135
NOXS-93 - Drug Profile 136
NR-001 - Drug Profile 137
paclitaxel albumin bound - Drug Profile 138
pazopanib hydrochloride - Drug Profile 150
S-588410 - Drug Profile 158
Synthetic Peptides for Rhabdomyosarcoma - Drug Profile 160
TAS-4464 - Drug Profile 161
tazemetostat - Drug Profile 162
VIMO-001 - Drug Profile 171
Rhabdomyosarcoma - Dormant Projects 172
Rhabdomyosarcoma - Discontinued Products 173
Appendix 174
Methodology 174
Coverage 174
Secondary Research 174
Primary Research 174
Expert Panel Validation 174
Contact Us 174
Disclaimer 175

List of Tables
Number of Products under Development for Rhabdomyosarcoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Rhabdomyosarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
Rhabdomyosarcoma - Pipeline by Celgene Corp, H1 2017
Rhabdomyosarcoma - Pipeline by CytRx Corp, H1 2017
Rhabdomyosarcoma - Pipeline by EpiZyme Inc, H1 2017
Rhabdomyosarcoma - Pipeline by Exelixis Inc, H1 2017
Rhabdomyosarcoma - Pipeline by Iproteos SL, H1 2017
Rhabdomyosarcoma - Pipeline by Ipsen SA, H1 2017
Rhabdomyosarcoma - Pipeline by MacroGenics Inc, H1 2017
Rhabdomyosarcoma - Pipeline by Novartis AG, H1 2017
Rhabdomyosarcoma - Pipeline by Noxxon Pharma AG, H1 2017
Rhabdomyosarcoma - Pipeline by Pfizer Inc, H1 2017
Rhabdomyosarcoma - Pipeline by Shionogi & Co Ltd, H1 2017
Rhabdomyosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
Rhabdomyosarcoma - Dormant Projects, H1 2017
Rhabdomyosarcoma - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Rhabdomyosarcoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *